2-phenyl-5-methyl-3-hexyn-2-ol | 56438-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-phenyl-5-methyl-3-hexyn-2-ol
• 英文别名: 5-Methyl-2-phenylhex-3-yn-2-ol
• CAS: 56438-39-2
• 化学式: C₁₃H₁₆O
• 分子量: 188.269
• InChiKey: JZPZNHCKERJEPM-UHFFFAOYSA-N

物化性质

• 沸点：
  312.2±30.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-phenyl-5-methyl-3-hexyn-2-ol 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Gold-Catalyzed Rearrangement of Alkynyl Donor–Acceptor Cyclopropanes To Construct Highly Functionalized Alkylidenecyclopentenes

  摘要：

  A gold-catalyzed 1,7-addition-cyclization-elimination cascade sequence performed on a range of alkynyl-substituted donor-acceptor-type cyclopropanes provides facile entry to highly functionalized exo-alkylidenecyclopentenes under very mild conditions. Isolation of the relevant allyl ether intermediate helped shed light on the reaction's mechanistic course.

  DOI：

  10.1021/acs.orglett.5b00671
• 作为产物：
  描述：

  3-甲基-1-丁炔 、 苯乙酮 在 正丁基锂 作用下， 以 甲苯 为溶剂， 反应 0.5h， 生成 2-phenyl-5-methyl-3-hexyn-2-ol
  参考文献：
  名称：

  Gold-Catalyzed Rearrangement of Alkynyl Donor–Acceptor Cyclopropanes To Construct Highly Functionalized Alkylidenecyclopentenes

  摘要：

  A gold-catalyzed 1,7-addition-cyclization-elimination cascade sequence performed on a range of alkynyl-substituted donor-acceptor-type cyclopropanes provides facile entry to highly functionalized exo-alkylidenecyclopentenes under very mild conditions. Isolation of the relevant allyl ether intermediate helped shed light on the reaction's mechanistic course.

  DOI：

  10.1021/acs.orglett.5b00671

文献信息

• Palladium/H⁺-cocatalyzed kinetic resolution of tertiary propargylic alcohols
  作者：Wanli Zhang、Shengming Ma

  DOI：10.1039/c8cc01949e

  日期：——

  A new approach to not-readily-available optically active tertiary propargylic alcohols through palladium/H+-cocatalyzed carboxylation of racemic tertiary propargylic alcohols with CO and MeOH has been described. Both enantiomers can be obtained with no less than 90% ee utilizing (R) or (S)-DTBM-Segphos. Various transformations of the optically active alcohols have been demonstrated.

  已经描述了通过钯/ H + -外消旋的叔炔丙醇与CO和MeOH的羧化羧化反应来制备尚未得到的旋光性叔炔丙醇的新方法。利用（R）或（S）-DTBM-Segphos，两种对映体都可以以不小于90％的ee获得。已经证明了旋光性醇的各种转化。
• Palladium catalyzed regioselective elimination–hydrocarbonylation of propargylic alcohols
  作者：Yuan Yuan、Minqiang Jia、Wanli Zhang、Shengming Ma

  DOI：10.1039/c9cc03262b

  日期：——

  A straightforward approach to synthesizing substituted 1,3-alkadien-2-yl carboxylic acids starting from readily available propargylic alcohols was developed. Based on mechanistic studies, the reaction was found to proceed via regioselective hydrocarbonylation of the C–C triple bonds of the in situ formed 1,3-enyne intermediates, providing 1,3-alkadien-2-yl carboxylic acids with a very high selectivity

  开发了一种从容易获得的炔丙醇开始合成取代的1,3-链二烯基-2-基羧酸的直接方法。根据机理研究，发现该反应是通过原位形成的1,3-烯炔中间体的C-C三键的区域选择性加氢羰基化进行的，从而提供具有非常高选择性的1,3-烷二烯-2-基羧酸。
• NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS
  申请人：Babaoglu Kerim

  公开号：US20130203727A1

  公开（公告）日：2013-08-08

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

  本发明提供了公式（I）的化合物或其盐，如本文所述。本发明还提供了包含公式I化合物的药物组合物，制备公式（I）化合物的过程，用于制备公式I化合物的中间体以及使用公式（I）化合物治疗哺乳动物的HIV病毒增殖，治疗艾滋病或延缓艾滋病或ARC症状发作的治疗方法。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160083368A1

  公开（公告）日：2016-03-24

  Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明揭示了化学式I的化合物或其盐。本发明还揭示了包括化合物I的药物组合物，制备化合物I的方法，用于制备化合物I的中间体以及治疗Retroviridae病毒感染，包括HIV病毒感染的治疗方法。
• Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US11166951B2

  公开（公告）日：2021-11-09

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

  磷脂酰肌醇 3-激酶（PI3K）抑制剂的治疗组合，包括对γ-和δ-异构体有选择性的 PI3K 抑制剂以及对γ-和δ-异构体均有选择性的 PI3K 抑制剂（PI3K-γ、PI3K-γ 和 PI3K-δ）、δ、PI3K-γ 和 PI3K-δ）的选择性抑制剂、Janus 激酶-2 (JAK-2) 抑制剂、布鲁顿酪氨酸激酶 (BTK) 抑制剂和/或 B 细胞淋巴瘤-2 (BCL-2) 抑制剂。在一些实施方案中，本发明提供了PI3K-δ抑制剂和BTK抑制剂、JAK-2和BTK抑制剂以及BCL-2和BTK抑制剂的治疗组合。